Stage 1B refers to being positive for both criteria.[59] However, the proposal of these substages is solely supported by studies focusing on the NGAL biomarker.[60,61] Further prospective trials are required to establish a similar definition of CSA-AKI for TIMP-2 and IGFBP-7 expression. This evidence concerns the gene TIMP2 and acute kidney injury.